Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
iStock Rating
D
Details...
Enter Symbol
Teva Pharmaceutical Industries (NASDAQ: TEVA)
Sector: Medical
Current Price :
$38.51
52 Week Low
$35.26
52 Week High
$50.90
Company
Overview
Research Notes
Company Profile
Competitors
Community
Wiki
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Related News
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Shares Outstanding:
941M
Market Cap:
$41.81B
Avg Volume:
3206468
P/E Ratio:
8.910
PEG Ratio:
0.960
Split:
On 7/1/2004 teva split by factor of 2.000
Trade now with
1m
3m
6m
1y
2y
Opinion and Analysis
Teva (TEVA) Cuts 2012 Earnings, Sales Guidance; Raises Margin View
May 24, 2012 09:09 AM |
TEVA
This Ignored Emerging Market Looks Like A Great Value Right Now
May 01, 2012 02:56 PM |
CBU
,
MLNX
,
TEVA
,
WTBA
A New Look At Teva?
Apr 19, 2012 09:20 AM |
TEVA
How I Approach Biotech Investing
Apr 18, 2012 12:01 PM |
AMGN
,
CELG
,
FRX
,
LLY
,
MRX
,
PFE
Pharma Spin-Off Should Unlock Value Of Covidien's Well-Positioned Device Business
Apr 10, 2012 03:53 PM |
ABT
,
BAX
,
BCR
,
BMY
,
DHR
,
ENDP
More Articles on TEVA..
Market News
ImmuPharma regains Lupuzor rights from Cephalon
Oct 25, 2011 06:39 AM |
TEVA
Antares receives US patent for VIBEX injector technology
Oct 07, 2011 09:40 AM |
AIS
,
TEVA
Pfizer wins Viagra patent-protection case
Aug 16, 2011 06:43 PM |
GSK
,
LLY
,
PFE
,
TEVA
Pfizer wins Viagra patent-protection case
Aug 16, 2011 12:46 PM |
GSK
,
LLY
,
PFE
,
TEVA
Pfizer wins Viagra patent-protection case
Aug 16, 2011 05:44 AM |
GSK
,
LLY
,
PFE
,
TEVA
More News on TEVA..
Press Releases
Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
May 24, 2012 08:26 AM |
TEVA
Teva to Host Conference Call and Webcast on May 24, 2012
May 23, 2012 05:00 PM |
TEVA
Teva UK Limited Launches new Website
May 18, 2012 01:00 AM |
TEVA
More Press Releases on TEVA..
SEC Filings
More SEC Filings on TEVA..
Sentiment Survey
Avg. Short Term
Bull 
Bear 
0
1
Avg. Long Term
Bull 
Bear 
1
0
Avg. Grade
More Details
Share Performance
Period
TEVA
Compare to S&P
YTD
9.99 %
1.14 %
4 Weeks
-0.25 %
0.67 %
12 Weeks
0.89 %
-0.43 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
27.20 %
EPS Growth in Last Year:
27.20 %
Sales Growth in Last Quarter:
30.66 %
Sales Growth in Last Quarter:
28.47 %
More...
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##